Topics

Glioblastoma | Treatment | Chemotherapy | Temozolomide | Targeted Therapy

Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Temozolomide > Targeted Therapy

2025

Brown NF, McBain C, Brazil L, Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C, Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland P.
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial.
Neurooncol Adv. 2025 May 26;7(1):vdaf032. doi: 10.1093/noajnl/vdaf032. PMID: 40800123. Interventional study. ˍ

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

2026

Nayab A, Mughal N, Angez M, Xing S, Burma AM, Balla H, Kizilbash SH, Yang X, Maqbool MA, Arain F, Hussain A, Amir S, Singh D, Karmali A, Somani S, Patel TR, Patel A, Hatanpaa KJ, Youssef M, Shaikh N, Ye C, Zhao D, Burma S, Sarkaria JN, Majd NK, Saleh M, Charest A, Miller CR, Nabors LB, Kataru MS, Tolbert CE, Jimenez F, Enam SA, Habib AA, Guo G.
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.
Sci Transl Med. 2026 Jul 8;18(857):eadx8398. doi: 10.1126/scitranslmed.adx8398. PMID: 42418561˰ ˍ
COMMENT
Yu X, Wu R, Cheng SY. Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.
Trends Pharmacol Sci. 2026 Aug 17:S0165-6147(26)00197-5. doi: 10.1016/j.tips.2026.07.010. PMID: 42608284. ˍ